Home  »  Trending   »  Looking Closely at the Growth Curve for Ginkgo Bio...

Looking Closely at the Growth Curve for Ginkgo Bioworks Holdings Inc. (DNA)

Ginkgo Bioworks Holdings Inc. (NYSE:DNA) went up by 2.68% from its latest closing price compared to the recent 1-year high of $15.86. The company’s stock price has collected -3.15% of loss in the last five trading sessions. Barron’s reported on 10/06/21 that Ginkgo Bioworks Stock Sinks on Short Seller Report

Is It Worth Investing in Ginkgo Bioworks Holdings Inc. (NYSE :DNA) Right Now?

Opinions of the stock are interesting as 4 analysts out of 7 who provided ratings for Ginkgo Bioworks Holdings Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


The average price from analysts is $7.48, which is $4.91 above the current price. DNA currently public float of 830.38M and currently shorts hold a 21.56% ratio of that float. Today, the average trading volume of DNA was 25.79M shares.

DNA’s Market Performance

DNA stocks went down by -3.15% for the week, with a monthly drop of -5.54% and a quarterly performance of 29.54%, while its annual performance rate touched -74.79%. The volatility ratio for the week stands at 10.10% while the volatility levels for the past 30 days are set at 8.83% for Ginkgo Bioworks Holdings Inc. The simple moving average for the period of the last 20 days is 9.25% for DNA stocks with a simple moving average of -29.65% for the last 200 days.

Analysts’ Opinion of DNA

Many brokerage firms have already submitted their reports for DNA stocks, with BofA Securities repeating the rating for DNA by listing it as a “Underperform.” The predicted price for DNA in the upcoming period, according to BofA Securities is $3 based on the research report published on May 18th of the current year 2022.

Cowen, on the other hand, stated in their research note that they expect to see DNA reach a price target of $12. The rating they have provided for DNA stocks is “Outperform” according to the report published on March 02nd, 2022.

Goldman gave a rating of “Neutral” to DNA, setting the target price at $7 in the report published on February 23rd of the current year.

DNA Trading at 2.79% from the 50-Day Moving Average

After a stumble in the market that brought DNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.65% of loss for the given period.

Volatility was left at 8.83%, however, over the last 30 days, the volatility rate increased by 10.10%, as shares surge +7.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.95% lower at present.

During the last 5 trading sessions, DNA fell by -3.15%, which changed the moving average for the period of 200-days by -73.05% in comparison to the 20-day moving average, which settled at $2.82. In addition, Ginkgo Bioworks Holdings Inc. saw -63.06% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for DNA

Current profitability levels for the company are sitting at:

  • -582.43 for the present operating margin
  • +53.93 for the gross margin

The net margin for Ginkgo Bioworks Holdings Inc. stands at -583.12. Equity return is now at value -191.90, with -143.20 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 12.79.

Is Cadence Bank (CADE) a Keeper?

Cadence Bank (NYSE:CADE) went down by -0.52% from its latest closing price compared to the recent 1-year high of $34.24. The company’s stock price has